Study protocol of the B-CAST study: a multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancer
Authors:
- Megumi IshiguroMIMegumi Ishiguro
- Kenjiro KotakeKKKenjiro Kotake
- Genichi NishimuraGNGenichi Nishimura
- Naohiro TomitaNTNaohiro Tomita
- Wataru IchikawaWIWataru Ichikawa
- Keiichi TakahashiKTKeiichi Takahashi
- Toshiaki WatanabeTWToshiaki Watanabe
- Tomohisa FuruhataTFTomohisa Furuhata
- Ken KondoKKKen Kondo
- Masaki MoriMMMasaki Mori
- Yoshihiro KakejiYKYoshihiro Kakeji
- Akiyoshi KanazawaAKAkiyoshi Kanazawa
Open Access
- 25 March 2013
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 149
Abstract
Background: Adjuvant chemotherapy for stage III colon cancer is internationally accepted as standard treatment with established efficacy. Several oral fluorouracil (5-FU) derivatives with different properties are available in Japan, but which drug is the most appropriate for each patient has not been established. Although efficacy prediction of 5-FU derivatives using expression of 5-FU activation/metabolism enzymes in tumors has been studied, it has not been clinically applied. Methods/design: The B-CAST study is a multicenter, prospective cohort study aimed to identify the patients who benefit from adjuvant chemotherapy with each 5-FU regimen, through evaluating the relationship between tumor biomarker expression and treatment outcome. The frozen tumor specimens of patients with stage III colon cancer who receives postoperative adjuvant chemotherapy are examined. Protein expression of thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF) are evaluated using enzyme-linked immunosorbent assay (ELISA). mRNA expression of TP, DPD, thymidylate synthase (TS) and orotate phosphoribosyl transferase (OPRT) are evaluated using reverse transcription polymerase chain reaction (RT-PCR). The patients’ clinical data reviewed are as follow: demographic and pathological characteristics, regimen, drug doses and treatment duration of adjuvant therapy, types and severity of adverse events, disease free survival, relapse free survival and overall survival. Then, relationships among the protein/mRNA expression, clinicopathological characteristics and the treatment outcomes are analyzed for each 5-FU derivative. Discussion: A total of 2,128 patients from the 217 institutions were enrolled between April 2009 and March 2012. The B-CAST study demonstrated that large-scale, multicenter translational research using frozen samples was feasible when the sample shipment and Web-based data collection were well organized. The results of the study will identify the predictors of benefit from each 5-FU derivative, and will contribute to establish the “personalized therapy” in adjuvant chemotherapy for colon cancer. Trial registration: ClinicalTrials.gov: NCT00918827, UMIN Clinical Trials Registry (UMIN-CTR) UMIN000002013Keywords
This publication has 22 references indexed in Scilit:
- Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trialBritish Journal of Cancer, 2012
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancerInternational Journal of Clinical Oncology, 2011
- Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC)Cancer Chemotherapy and Pharmacology, 2010
- A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?European Journal of Cancer, 2009
- Capecitabine as Adjuvant Treatment for Stage III Colon CancerNew England Journal of Medicine, 2005
- The epidermal growth factor receptor as a target for colorectal cancer therapySeminars in Oncology, 2005
- Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trialLangenbeck's Archives of Surgery, 2002
- Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues.International Journal of Oncology, 2000
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnti-Cancer Drugs, 1996
- Preparation of Anti-human Thymidine Phosphorylase Monoclonal Antibodies Useful for Detecting the Enzyme Levels in Tumor Tissues.Biological and Pharmaceutical Bulletin, 1996